Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Lacy

Showing results (511-520 of 553) with videos related to

Pageof 56
Sort By:
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
The Journal of Infectious Diseases|July 4, 1998
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responseR R MacGregor, J D Boyer, K E Ugen, et al.
Ebiomedicine|April 9, 2019
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural statesGiulia Pellizzari, Coran Hoskin, Silvia Crescioli, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Rome Foundation and international neurogastroenterology and motility societies' consensus on idiopathic gastroparesisJolien Schol, I-Hsuan Huang, Florencia Carbone, et al.
The American Journal of Gastroenterology|November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialPhilip Schoenfeld, Brian E Lacy, William D Chey, et al.
Clinical Immunology (Orlando, Fla.)|January 13, 1999
Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trialJ D Boyer, M A Chattergoon, K E Ugen, et al.
Expert Review of Clinical Immunology|February 23, 2022
BRAF inhibitors and their immunological effects in malignant melanomaRebecca Adams, Jack E M Coumbe, Ben G T Coumbe, et al.
Oncotarget|November 5, 2017
BRAF inhibitors: resistance and the promise of combination treatments for melanomaMerope Griffin, Daniele Scotto, Debra H Josephs, et al.
Expert Review of Clinical Immunology|March 27, 2024
Tumor associated macrophages as key contributors and targets in current and future therapies for melanomaShabana Habib, Gabriel Osborn, Zena Willsmore, et al.
Oncoimmunology|May 10, 2019
Immune mediator expression signatures are associated with improved outcome in ovarian carcinomaMano Nakamura, Heather J Bax, Daniele Scotto, et al.
Pageof 56

Showing results (511-520 of 553) with videos related to

Sort By:
Pageof 56
Plos One|July 30, 2015
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled TrialBrian E Lacy, Ron Schey, Steven J Shiff, et al.
The Journal of Infectious Diseases|July 4, 1998
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responseR R MacGregor, J D Boyer, K E Ugen, et al.
Ebiomedicine|April 9, 2019
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural statesGiulia Pellizzari, Coran Hoskin, Silvia Crescioli, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Rome Foundation and international neurogastroenterology and motility societies' consensus on idiopathic gastroparesisJolien Schol, I-Hsuan Huang, Florencia Carbone, et al.
The American Journal of Gastroenterology|November 2, 2017
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialPhilip Schoenfeld, Brian E Lacy, William D Chey, et al.
Clinical Immunology (Orlando, Fla.)|January 13, 1999
Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trialJ D Boyer, M A Chattergoon, K E Ugen, et al.
Expert Review of Clinical Immunology|February 23, 2022
BRAF inhibitors and their immunological effects in malignant melanomaRebecca Adams, Jack E M Coumbe, Ben G T Coumbe, et al.
Oncotarget|November 5, 2017
BRAF inhibitors: resistance and the promise of combination treatments for melanomaMerope Griffin, Daniele Scotto, Debra H Josephs, et al.
Expert Review of Clinical Immunology|March 27, 2024
Tumor associated macrophages as key contributors and targets in current and future therapies for melanomaShabana Habib, Gabriel Osborn, Zena Willsmore, et al.
Oncoimmunology|May 10, 2019
Immune mediator expression signatures are associated with improved outcome in ovarian carcinomaMano Nakamura, Heather J Bax, Daniele Scotto, et al.
Pageof 56